Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity

Bibliography

• Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005;434:214-17
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Guidelines for the treatment of malaria. Geneva, Switzerland; 2010. p. 194. Available from: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf
   Google Scholar
• Fidock DA. Drug discovery: priming the antimalarial pipeline. Nature 2010;465:297-8
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Fairhurst RM, Slutsker L, et al. The threat of artemisinin-resistant malaria. N Engl J Med 2011;365:1073-5
   PubMed Web of Science ®Google Scholar
• Cibulskis RE, Bell D, Christophel E-M, et al. Estimating Trends in the Burden of Malaria at Country Level. Am J Trop Med Hyg 2007;77:133-7
   PubMed Web of Science ®Google Scholar
• Wiwanitkit V. New emerging drug-resistant malaria. Int J Gen Med 2010;3:327-9
   PubMedGoogle Scholar
• Walsh JJ, Bell A. Hybrid drugs for malaria. Curr Pharm Des 2009;15:2970-85
   PubMed Web of Science ®Google Scholar
• Dechy-Cabaret O, Benoit-Vical F, Loup C, et al. Synthesis and antimalarial activity of trioxaquine derivatives. Chemistry 2004;10:1625-36
   PubMed Web of Science ®Google Scholar
• Opsenica I, Opsenica D, Lanteri CA, et al. New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton. J Med Chem 2008;51:6216-19
   PubMed Web of Science ®Google Scholar
• Feng T-S, Guantai EM, Nell M, et al. Effects of highly active novel artemisinin-chloroquinoline hybrid compounds on beta-hematin formation, parasite morphology and endocytosis in Plasmodium falciparum. Biochem Pharmacol 2011;82:236-47
   PubMed Web of Science ®Google Scholar
• Andayi WA, Egan TJ, Gut J, et al. Synthesis, Antiplasmodial activity, and beta-hematin inhibition of hydroxypyridone–chloroquine hybrids. ACS Med Chem Lett 2013;4:642-6
   PubMedGoogle Scholar
• Masimirembwa CM, Hasler JA, Johansson I. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 1995;48:35-8
   PubMed Web of Science ®Google Scholar
• Bapiro TE, Egnell A-C, Hasler JA, Masimirembwa CM. Application of higher throughput screening (hts) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 2001;29:30-5
   PubMed Web of Science ®Google Scholar
• Hershko C, Theanacho EN, Spira DT, et al. The effect of N-alkyl modification on the antimalarial activity of 3- hydroxypyridin-4-one oral iron chelators. Blood 1991;77:637-43
   PubMed Web of Science ®Google Scholar
• Kaschula CH, Egan TJ, Hunter R, et al. Structure and activity relationships in 4-aminoquinoline antiplasmodials. The role of the group at the 7-position. J Med Chem 2002;45:3531-9
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26
   PubMed Web of Science ®Google Scholar
• ChemAxon property calculator plugins. Available from: http://www.chemaxon.com/marvin
   Google Scholar
• de Aquino Ribeiro JA, de Campos LMM, Alves RJ, et al. Efavirenz related compounds preparation by hydrolysis procedure: setting reference standards for chromatographic purity analysis. J Pharm Biomed Anal 2007;43:298-303
   PubMed Web of Science ®Google Scholar
• Patel P, Osechinskiy S, Koehler J, et al. Micro parallel liquid chromatography for high-throughput compound purity analysis and early ADMET profiling. J Assoc Lab Autom 2004;9:185-91
   Google Scholar
• MOKA. Available from: http://www.moldiscovery.com/software/MOKA
   Google Scholar
• Turbidimetric solubility assay. Available from: http://www.cyprotex.com/admepk/physicochemical-properties/turbidimetricsolubility/
   Google Scholar
• Vilá J, Obach R, Prieto R, Moreno J. Liquid chromatographic capacity factor as an indicator of lipophilicity in a series of betablocker drugs. Chromatographia 1986;22:48-50
   Web of Science ®Google Scholar
• Wiczling P, Kawczak P, Nasal A, Kaliszan R. Simultaneous Determination of pKa and Lipophilicity by Gradient RP HPLC. Anal Chem 2006;78:239-49
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Bredberg U, Andersson T. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 2003;42:515-28
   PubMed Web of Science ®Google Scholar
• Thompson T. Early ADME in support of drug discovery: the role of metabolic stability studies. Curr Drug Metab 2000;1:215-41
   PubMed Web of Science ®Google Scholar
• Barter Z, Bayliss M, Beaune P, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007;8:33-45
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab and Dispos 2005;33:1304-11
   PubMed Web of Science ®Google Scholar
• Houston BJ, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997;29:891-922
   PubMed Web of Science ®Google Scholar
• Crespi CL, Miller VP, Penman W. Assays for cytochrome P450 inhibition. Anal Biochem 1997;248:188-90
   PubMed Web of Science ®Google Scholar
• Thelingwani RS, Zvada SP, Hugues D, et al. In vitro and in silico identification and characterisation of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metab Dispos 2009;37:1286-12894
   PubMed Web of Science ®Google Scholar
• Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 2011;10:197-208
   PubMed Web of Science ®Google Scholar
• Pang KS, Roland M. Hepatic clearance of drugs I: theoretical considerations of a well-stirred and parallel-tube model. Influence of hepatic blood flow, plasma and blood cell binding and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977;5:625-53
   PubMedGoogle Scholar
• Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin Pharmacokinet 1996;30:263-99
   PubMed Web of Science ®Google Scholar